My pre-market scanner caught something big this morning. EDSA lit up across every single filter I run, and when I dug into the details, I knew this was going to be a teaching moment. The setup doesn't lie, and this one's textbook.

The Bohen Score came in at 95 out of 100 with a clean A+ grade and full 5-bar signal strength. Here's what made this so compelling: Momentum scored a near-perfect 20/20, Volume Surge maxed out at 25/25, Float hit the sweet spot at 15/15, and the FDA catalyst factor delivered another perfect 15/15. Setup Quality came in strong at 20/25, just shy of perfection but still in elite territory.

Let me break down the Bohen Levels for you. My Stop Out sits at $1.92 - that's my line in the sand, and below that level, I'm out, no questions asked. The key Breakout level comes in at $2.58, and this is where the real action starts. Above that breakout point, we're looking at a momentum shift that could attract serious attention.

The Target level sits at $2.87, with the Stretch goal up at $3.24. Here's the math that matters: we're looking at a 1:2.4 risk-reward ratio. Risk per share comes in at just $0.28, while the upside to target offers $0.67 per share. That's the kind of asymmetric setup that gets my attention every time.

What can you learn from this scoring methodology? When Volume Surge maxes out and Momentum scores this high, it tells us the market is already paying attention. The FDA catalyst factor hitting 15/15 means we've got a fundamental driver that could sustain any move. But here's the key - even with a 95 score, I still need to see price action respect these levels.

In today's choppy market environment, having a clear catalyst like FDA news combined with technical confirmation is exactly what we want to see. The biotech sector has been volatile, but that volatility creates opportunity when you've got the right filters in place. This is why I always say: let the scanner do the work.

Trade what you see, not what you think. The Bohen Score gives us the framework, the levels give us the roadmap, but price action is still king. Set up your scanner, trust the process, and remember - the setup doesn't lie when all the factors align like this.